Nachrichten zur Iovance Biotherapeutics Inc. Aktie

Why Iovance Biotherapeutics Tumbled by Nearly 6% Today

Iovance Biotherapeutics (NASDAQ: IOVA) didnt quite end the stock trading week on a high note. The companys shares were dinged…

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”),…

Is This Beaten-Down Stock a Buy Near Its 52-Week Low?

Penny stocks -- companies with shares trading at around $5 or even less apiece -- usually carry above-average risk. However,…

Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity

…

3 Monster Stocks in the Making

Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.…

Why Iovance Biotherapeutics Stock Is Crashing Today

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday. The huge decline…

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”),…

Is Iovance Biotherapeutics a Millionaire-Maker?

Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up…

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year,…

1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street

Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached…

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”),…

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 3.70% and 2.26%, respectively, for the quarter ended December 2024. Do…

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”),…

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

Iovance Biotherapeutics (IOVA) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”),…

Whats Wrong With Iovance Biotherapeutics Stock?

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. The stock soared…

Where Will Iovance Biotherapeutics Be in 5 Years?

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients…

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”),…

3 Mid-Cap Stocks That Could Take Off in 2025

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have…

Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today

Now this is a fine way for a stock to greet the new year. On the back of a glowing…

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”),…

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are…

Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isnt

…

Prediction: This Stock Will Beat the Market in 2025

It hasnt been a great year for Iovance Biotherapeutics (NASDAQ: IOVA), an innovative mid-cap biotech company. The drugmakers shares have…

Iovance Biotherapeutics: Steady Progress

…

Is Iovance Biotherapeutics Stock a Millionaire Maker?

The biotech industry has been described as the Wild West of the stock market. Although some companies manage to develop…

Got $1,500? Buy Iovance Biotherapeutics Now and Dont Look Back

As the rising star of cell therapy biotechs, Iovance Biotherapeutics (NASDAQ: IOVA) is a hot stock thats capturing a lot…

Got $1,500? Buy Iovance Biotherapeutics Now and Dont Look Back

…

2 Innovative Stocks That Could Deliver Outsize Returns

Many of Wall Streets largest and most successful stocks became so thanks to innovation. Its too late to get in…

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More

Biotechs often need several years to realize their visions, even after they have a drug approved for the first time.…

Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity

…

Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript

…

Is Iovance Biotherapeutics Stock a Buy?

The biotech is making important breakthroughs, but is that enough?…

Iovance Biotherapeutics: Moving To The Next Phase

…

3 Reasons to Buy Iovance Biotherapeutics Stock Like Theres No Tomorrow @themotleyfool #stocks $IOVA

This biotechs growth story is going to start moving faster, and soon.…

3 Reasons to Buy Iovance Biotherapeutics Stock Like Theres No Tomorrow

This biotechs growth story is going to start moving faster, and soon.…

3 Things You Need to Know if You Buy Iovance Biotherapeutics Today

Theres plenty of upside with this stock, but it might take a while to realize.…

3 Things You Need to Know if You Buy Iovance Biotherapeutics Today @themotleyfool #stocks $IOVA

Theres plenty of upside with this stock, but it might take a while to realize.…

Iovance Therapeutics: Historic Product, Tough Commercial Outlook

…

Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”),…

Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?

This companys new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace.…

Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years? @themotleyfool #stocks $IOVA

This companys new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace.…

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”),…

This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock

It could demonstrate a few capabilities that no other biotech has as of yet.…

Iovance Biotherapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation

…

Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell? @themotleyfool #stocks $IOVA $MRK $PIPR $SF

Find out how concerned investors should be about setbacks for this companys revolutionary new cancer therapies.…

Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?

Find out how concerned investors should be about setbacks for this companys revolutionary new cancer therapies.…

Why Iovance Biotherapeutics Stock Stumbled Today

One pundit warns of apparent manufacturing issues with the companys melanoma drug.…

Iovance Biotherapeutics downgraded to Neutral at Piper Sandler, stock falls

…

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”),…